BiotechTube
DIVERCHIM CDMO

DIVERCHIM CDMO

Paris, France· Est.
diverchim.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DIVERCHIM CDMO is a specialized French contract development and manufacturing organization focused on high-value, low-volume small molecule active ingredients. It leverages over 20 years of collective expertise to serve niche markets such as orphan drugs, radiopharmaceuticals, and novel therapeutic modalities like antisense oligonucleotides (ASOs). With a GMP and FDA-registered site, the company offers integrated services from route scouting to commercial manufacturing, positioning itself as a key partner for emerging biotechs and larger players in targeted therapies.

Orphan Drugs/Rare DiseasesOncology (via Radiopharmaceuticals)Various (via CDMO services)

Technology Platform

Specialized small molecule and oligonucleotide CDMO platform with expertise in Internal Vectorized Radiochemistry (IVR), Solid Phase Peptide Synthesis, lyophilization, aliquoting, and development of antisense oligonucleotides (ASOs).

Opportunities

The rapid growth of targeted radiopharmaceuticals and orphan drugs creates strong demand for specialized, small-volume manufacturing.
Expansion into oligonucleotide (ASO) manufacturing represents a significant new market adjacency with high growth potential.
Its FDA-ready status and European location position it well to capture transatlantic client projects.

Risk Factors

Reliance on a limited number of complex client projects creates concentration risk.
Technical failure in scaling novel chemistries could damage reputation and revenue.
Faces competition from both larger CDMOs expanding into niches and other specialized boutiques.

Competitive Landscape

DIVERCHIM competes in the niche segment of small-volume, high-complexity CDMO services. It differentiates itself through specific expertise in radiopharmaceutical precursors and a move into oligonucleotides, competing against other specialized boutiques and the niche service arms of larger CDMOs. Its main competitive advantages are its focus, flexibility, and deep expertise in complex small molecule synthesis at limited scale.

More companies in Small Molecule Drugs →More companies in France →